IceCure Medical Ltd. is a commercial-stage medical device company specializing in liquid-nitrogen-based cryoablation systems for the minimally invasive treatment of benign and malignant tumors. Its flagship product, the ProSense Cryoablation System, uses ultra-cold temperatures to freeze and destroy tumors, offering a convenient alternative to surgery in office-based or CT room procedures. The company focuses on women's health and interventional oncology, targeting applications such as low-risk breast cancer, breast fibroadenomas, kidney tumors, lung cancer, and palliative care. ProSense supports quick procedures with high efficacy, backed by clinical studies demonstrating strong tumor destruction rates and physician satisfaction. IceCure Medical Ltd. also develops next-generation systems like XSense for expanded indications. Commercially available worldwide, the technology enables patient-centered care choices in tumor ablation across multiple cancer types. Founded in 2006 and headquartered in Caesarea, Israel, IceCure Medical Ltd. remains dedicated to advancing cryoablation as a focused, data-driven solution in oncology.